Based on the available information, there is no explicit mention of any plans to extend the patent for Tigecycline injection globally.
The first source, a drug patent watch website, provides information about the patent for Tigecycline but does not mention any plans for global patent extensions [1]. The second source, from the United States Patent and Trademark Office, discusses the process of patent term extensions under U.S. law, but it does not contain specific information about Tigecycline or any global patent extension plans [2].
However, the third source does provide some relevant information. It announces a license and collaboration agreement between Shionogi & Co., Ltd., and the Global Antibiotic Research and Development Partnership (GARDP) and Chai Biotechnology Co., Ltd. for the treatment of bacterial infections [3]. This agreement aims to expand access to Cefiderocol in 135 countries [3]. While this news pertains to Cefiderocol and not Tigecycline, it does suggest that Shionogi, the company that originally developed Tigecycline, is actively involved in negotiations and agreements related to antibiotic treatments on a global scale.
In conclusion, while there is no direct evidence of plans to extend the Tigecycline injection patent globally, the involvement of Shionogi in global antibiotic-related agreements suggests a possibility. It would be advisable to monitor official company announcements or statements for any updates regarding Tigecycline's patent status.
Sources:
[1] Drug Patent Watch. (n.d.). Tigecycline. Retrieved from https://www.drugpatentwatch.com/p/tradename/TIGECYCLINE
[2] U.S. Patent and Trademark Office. (n.d.). Patent Terms Extended Under 35 U.S.C. 156. Retrieved from https://www.uspto.gov/patents/laws/patent-term-extension/patent-terms-extended-under-35-usc-156
[3] Shionogi. (2022, June 28). SHIONOGI, GARDP and Chai Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries. Retrieved from https://www.shionogi.com/us/en/news/2022/06/shionogi-gardp-and-chai-announce-landmark-license-and-collaboration-agreements-to-treat-bacterial-infections-by-expanding-access-to-cefiderocol-in-135-countries.html